Punzi Simona, Cittaro Davide, Gatti Guido, Crupi Gemma, Botrugno Oronza A, Cartalemi Antonino Alex, Gutfreund Alon, Oneto Caterina, Giansanti Valentina, Battistini Chiara, Santacatterina Giovanni, Patruno Lucrezia, Villanti Ilaria, Palumbo Martina, Laverty Daniel J, Giannese Francesca, Graudenzi Alex, Caravagna Giulio, Antoniotti Marco, Nagel Zachary, Cavallaro Ugo, Lanfrancone Luisa, Yap Timothy A, Draetta Giulio, Balaban Nathalie, Tonon Giovanni
Functional Genomics of Cancer Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Università Vita-Salute San Raffaele, Milan, Italy.
Nat Commun. 2025 Feb 3;16(1):1291. doi: 10.1038/s41467-024-54728-7.
Bacteria withstand antibiotic treatment through three alternative mechanisms: resistance, persistence or tolerance. While resistance and persistence have been described, whether drug-induced tolerance exists in cancer cells remains largely unknown. Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. After prolonged drug exposure, such tolerant responses morph into persistence, whereby the increased DNA damage repair is entirely reversed. The central regulator of mitophagy PINK1 drives this reduction in DNA repair via the cytoplasmic relocalization of the cell identity master HNF4A, thus hampering HNF4A transcriptional activation of DNA repair genes. We conclude that exposing cancer cells to relevant standard-of-care antitumour therapies induces a pervasive drug-induced tolerant response that might be broadly exploited to increase the impact of first-line, adjuvant treatments and debulking in advanced cancers.
耐药性、持留性或耐受性。虽然耐药性和持留性已有相关描述,但癌细胞中是否存在药物诱导的耐受性在很大程度上仍不清楚。在此,我们表明,人类癌细胞在暴露于常用化疗方案时会引发耐受性反应,这是由自噬的广泛激活所推动的,导致DNA损伤修复途径的全面激活。长时间药物暴露后,这种耐受性反应会转变为持留性,此时增加的DNA损伤修复会完全逆转。线粒体自噬的核心调节因子PINK1通过细胞身份主控因子HNF4A的细胞质重新定位驱动DNA修复的减少,从而阻碍HNF4A对DNA修复基因的转录激活。我们得出结论,将癌细胞暴露于相关的标准抗肿瘤治疗中会诱导广泛的药物诱导耐受性反应,这可能被广泛利用以增强一线、辅助治疗以及晚期癌症减瘤治疗的效果。